HOUSTON, Texas - March 1, 2005 - Cell>Point obtained the worldwide patent and technology license on February 14, 2005 to tatraazacyclopentadecane (N4) technology developed at The University of Texas M.D. Anderson Cancer Center. N4 Technology will form the foundation for the development of Positron Emission Tomography imaging agents using generator based isotopes as well as compounds for imaging and treating neuroendocrine tumors and certain diseases affecting the central nervous system.